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In 2010, the World Health Organization (WHO) 
with resolution WHA63.12, urged all Member States to 
implement Patient Blood Management (PBM)1. In Italy, 
the National Blood Centre, the governmental authority 
entrusted with the coordination of the blood system, 
in line with the aforementioned resolution, included 
the implementation of a PBM programme among 
the objectives of the 2012 national self-sufficiency 
plan for blood and blood components2. According to 
the Health Ministry Decree of 4th September 2012, 
regarding the aforementioned self-sufficiency plan, the 
concept of PBM was first introduced as a tool to pursue 
the objective of achieving national self-sufficiency. 
To reach this goal the Decree established that it was 
necessary to define and implement innovative and 
more effective methods and measure to ensure the 
appropriate clinical and organisational management 
of blood.
The 2013 programme dealt with the same issue, 
introducing clearly the wording PBM and underlining 
the need to promote a multidisciplinary and evidence-
based approach aimed at improving the patient's 
outcome through the three pillars of PBM3. 
In Italy, in 2013 more than 170,000 arthroplasties 
were performed in 750 facilities with an impact on 
healthcare expenditure, only for surgical diagnosis-
related groups, close to 1.5% of the national healthcare 
fund4. Therefore, in the 2014 national self-sufficiency 
plan a project, coordinated by the National Blood 
Centre, foreseeing the first pilot application in the field 
of elective major orthopaedic replacement surgery 
was introduced5. This project was launched in the 
orthopaedic units of two large university hospitals in 
the Regions of Tuscany and Emilia Romagna. 
The 2015 national self-sufficiency plan confirmed 
and took into account a drop in red blood cell 
transfusion possibly associated with an increased 
awareness of PBM techniques and strategies that 
once again were defined as indispensable tools to 
ensure national self-sufficiency also for that year6. 
Contemporarily, multidisciplinary guidelines on PBM 
in elective orthopaedic surgery were published7. The 
recommendations were produced by a working group 
coordinated by the Italian National Blood Centre and 
involving five scientific societies (the Italian Society 
of Transfusion Medicine and Immunohaematology 
[SIMTI]; the Italian Society of Italian Society of 
Orthopaedics and Traumatology [SIOT]; the Italian 
Society of Anaesthesia, Analgesia, Resuscitation and 
Intensive Therapy [SIAARTI]; the Italian Society for 
the Study of Haemostasis and Thrombosis [SISET], 
and the National Association of Hospital Medical 
Directors [ANMDO])8. In the same year, thanks to the 
endorsement of PBM by the Italian Health Ministry, 
a very important Decree was issued by the Health 
Minister regarding provisions related to quality and 
safety requirements of blood and blood components9. 
Article 25 "Transfusion safety", Paragraph 5 of this 
Decree9 states that "For the prevention of avoidable 
transfusions and with particular reference to the 
preparation of the patient who will undergo pre-
scheduled surgical treatments, specific programmes are 
defined and implemented nationwide (Patient Blood 
Management) on the basis of guidelines to be issued 
by the National Blood Centre within six months from 
the entry into force of the present Decree". 
The 2016 self-sufficiency national plan stated that 
the aforementioned regulatory guidelines had to be 
based on the scientific recommendations on PBM 
recently published in the journal Blood Transfusion7. A 
set of 32 recommendations with a pragmatic approach 
to implementing a PBM programme were, therefore, 
published (Table I). The objectives of this guideline 
include effective use of pre-operative clinics10, 
management of peri-operative anaemia11-13, detection 
and treatment of any nutritional deficiencies with 
haematinics (including intravenous administration of 
iron when necessary14,15), improvement of peri-operative 
© 
SIM
TI 
Se
rvi
zi 
Srl
All rights reserved - For personal use only 
No other use without premission
2Vaglio S et al
Blood Transfus DOI 10.2450/2017.0060-17
Table I - Guidelines for the implementation of Patient Blood Management.
 Recommendations for the pre-, intra- and post-operative period
1 Patients with acquired or congenital coagulopathies and/or thrombocytopathies or positive bleeding anamnesis or those being treated with 
anticoagulants and/or anti-platelet drugs shall be managed in cooperation with haemostasis and thrombosis specialists.
2 In all adult, clinically stable inpatients who are to undergo a homologous or autologous red blood cell (RBC) transfusion, the adoption of a restrictive 
transfusion threshold established in cooperation with a transfusion medicine specialist, is recommended. These include critical patients, those with 
a history of cardiovascular pathologies and those who are to undergo orthopaedic or heart surgery.
3 The threshold for homologous or autologous RBC transfusions in other categories of patients, shall be adopted in cooperation with a transfusion 
medicine specialist.
4 In clinically stable inpatients needing homologous or autologous RBC transfusions a single unit blood transfusion policy shall be adopted. Further 
RBC units shall be transfused after a thorough clinical reassessment of the patient.
5 When patients with thrombocytopenia, acquired platelet disorders, or disseminated intravascular coagulation undergo major elective surgery and 
clinically relevant bleeding or bleeding in vital organs is expected, a prophylactic transfusion of platelet concentrates is suggested. The transfusion 
threshold, timing and modality shall be established in cooperation with a transfusion medicine specialist. 
6 Predeposit autologous blood donation programmes shall be carried out pursuant to the pertinent law in force*. 
* At the moment, predeposit autologous donation is indicated for: i) patients with rare erythrocyte phenotype or with complex alloimmunisations 
for whom it is difficult to obtain compatible homologous blood components; ii) donors of bone marrow haematopoietic stem cells; iii) children 
who are to undergo scoliosis surgery9.
7 The volume and frequency of blood samples for laboratory tests shall be minimised to prevent iatrogenic anaemia.
Recommendations for the pre-operative period
8 The preparation of patients who are to undergo non-oncologic major elective surgery, and are expected to have clinically relevant peri-operative 
bleeding, foresees a careful pre-operative evaluation through clinical and laboratory investigations aimed at providing an exhaustive personal and 
family anamnesis, detecting anaemia (to minimise homologous RBC transfusion that can lead to a negative outcome), optimising erythropoiesis, 
identifying and managing bleeding risk as well as assessing and optimising their individual physiological tolerance of anaemia (through the evaluation 
of cardio-respiratory functional reserve when necessary), and identifying risk factors. The evaluation should be carried out at least 30 days before 
the planned date of the operation, in order to enable more detailed investigations and/or arrange appropriate treatment.
9 It is recommended that all adult patients who are candidates for elective major surgery for which a multidisciplinary programme of co-ordinated 
interventions has been established involving the adoption of pharmacological and non-pharmacological techniques aimed at optimising erythropoiesis, 
minimising blood losses and optimising tolerance of anaemia, before giving consent to one or more of the above-mentioned treatments, receive 
detailed information on their clinical state and strategies to limit homologous transfusion needs included in the local patient blood management 
programme; explanatory material prepared ad hoc by the hospital may be used for this purpose.
10 The haemoglobin (Hb) target value before elective major surgery shall be within the normal range according to World Health Organization (WHO) 
criteria.
11 Anaemia is defined according to Hb threshold values indicated by the WHO.
12 If a state of anaemia is detected, the subsequent laboratory tests shall be performed with the aim of identifying iron or other nutritional deficiencies 
(folic acid and/or vitamin B12), chronic kidney disease and/or chronic inflammatory disorders.
13 Since the pre-operative Hb value is the main, independent risk factor for an RBC transfusion, any nutritional deficiencies (iron, vitamin B12, folate), 
once detected, shall be treated with haematinics.
14 In the event of iron deficiency being detected, when the oral administration of iron is ineffective or not tolerated, or when the elective major surgery 
is scheduled for less than four weeks after anaemia has been diagnosed, the intravenous administration of iron is suggested.
15 Following an appropriate evaluation, to avoid a functional deficiency of iron in patients during treatment with erythropoietic growth factor, it is 
suggested that intravenous iron be administered.
16 When the administration of intravenous iron is necessary, the utilisation of a single high-dose preparation for the repletion of iron in storage sites 
is suggested.
Continued on next page.
haemostasis16,17, reduction of blood sample volumes, 
implementation of restrictive transfusion triggers18,19 
and promotion of a single-unit transfusion policy, to 
begin with. The active participation of haemostasis and 
thrombosis as well as blood transfusion specialists is 
foreseen in the multidisciplinary group that has the task 
to put into effect the local PBM programme.
Intentionally, no recommendation on the period 
of time that red blood cells should be stored prior to 
transfusion was included because we have a decreasing 
interest in the "new blood - old blood" diatribe 
and rather agree with the necessity to welcome the 
opportunity -omics/laboratory studies provided us with 
to further improve storage quality20-22. 
In January 2017, the Health Ministry sent the 
guideline to the Italian Regions and invited them 
to ensure that all health facilities applied it in order 
to deliver effective healthcare, reduce the need 
for (homologous) transfusion, improve patients' 
assistance and reduce costs, including those related 
to transfusion therapy. Through the Regional Blood 
Centres, the National Blood Centre will utilise ad-hoc 
key performance indicators to be developed to monitor 
the application of the guideline.
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Table I - Guidelines for the implementation of Patient Blood Management (continued from previous page).
Recommendations for the intra-operative period
17 As a pharmacological alternative to improve oxygen transport to correct bleeding-induced hypovolaemia, it is recommended that crystalloid or 
protein-free colloid solutions be used as first-line therapy, with albumin 5% solution as second-line therapy, when crystalloid or non-protein colloid 
solutions have already been used at maximum doses, without having produced an adequate clinical response, and when non-protein colloids are 
contraindicated.
18 With the purpose of containing intra-operative bleeding effectively during elective surgery, it is suggested that combinations of appropriate surgical 
techniques and instruments to reduce blood loss, minimise trauma to tissues and vessels and promote local haemostasis, which can also be aided 
by the local administration of vasoconstrictive drugs, be used.
19 With the aim of managing fluid therapy, preference should be given to continuous or semi-continuous haemodynamic monitoring based on the 
evaluation of flow rather than pressure.
20 It is suggested that intra-operative fluid administration protocols based on haemodynamic optimisation be adopted.
21 In patients who are to undergo surgery where clinically relevant bleeding is expected but who do not have risk factors for hypercoagulability in the 
preoperative anamnesis, the utilisation of tranexamic acid is suggested. 
22 It is recommended that intra-operative blood recovery be used in major surgery in cases in which blood loss is expected to be at least 1,000 mL 
or in any case ≥20% of the patient's volaemia despite adopting multimodal strategies, including the use of pharmacological, surgical and 
anaesthesiological blood-conservation techniques, and intra-operative cell salvage.
23 It is recommended that point-of-care (POC) instruments be used for the non-invasive continuous measurement of Hb and haematocrit levels.
24 It is suggested that POC instruments be used for the overall monitoring of haemostasis with the purpose of managing clotting factor replacement 
therapy and limiting the use of transfusion with blood components in elective major heart surgery and all operations with a high risk of bleeding 
or in the presence of major bleeding.
25 In the presence of massive bleeding during elective major surgery and in association with the correction of the triggering cause, it is suggested that 
severe hypofibrinogenaemia (<1 g/L) which persists despite treatment with fresh-frozen plasma be treated with fibrinogen concentrate° or, if not 
available, with cryoprecipitate. 
26 In the presence of massive bleeding during elective major surgery and in association with the correction of the triggering cause during massive 
transfusion, it is suggested that treatment with fibrinogen concentrate°, or if not available with cryoprecipitate, be considered to prevent the fibrinogen 
level from falling below 1 g/L, the critical threshold for haemostasis. 
27 The administration of fibrinogen concentrate°, or if not available cryoprecipitate, is to be preferred to fresh-frozen plasma when there are 
contraindications to volume overloading.
° Currently, fibrinogen concentrate is not registered in Italy for this use.
Recommendations for the post-operative period
28 The utilisation of POC instruments for the non-invasive continuous measurement of Hb and haematocrit levels is suggested.
29 When the administration of iron is necessary, an intravenous therapy is recommended, and where possible through the utilisation of a single high-
dose preparation for the repletion of iron in storage sites.
30 Post-operative blood salvage is recommended only in cases where the post-operative blood loss is expected to be ≥10% of the patient's volaemia 
despite implementing multimodal strategies, including the integrated use of other pharmacological, surgical and anaesthesiological blood-conservation 
techniques. 
31 When post-operative cell salvage is utilised, the use of blood-washing systems is to be preferred.
32 When using non-washing systems, it is suggested that the concentration of free Hb be determined before re-infusing the blood to ensure that the 
level of haemolysis is less than 0.8% of the red cell mass contained in the product transfused.© 
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